SARS-CoV-2 envelope protein T cell epitopes

The term "SARS-CoV-2 envelope protein T cell epitopes" refers to specific peptide sequences derived from the SARS-CoV-2 envelope (E) protein that are recognized by T cells when presented by major histocompatibility complex (MHC) class I or II molecules. The E protein is the smallest structural protein of SARS-CoV-2, embedded in the viral lipid envelope, and plays roles in virus assembly, release, pathogenesis, and ion channel activity as a viroporin.[1][2][3] These epitopes have been identified through epitope prediction tools and databases like IEDB, with examples showing binding to various HLA alleles such as HLA-B*1501 for MHC-I and HLA-DRB1*04:01 for MHC-II, potentially eliciting antiviral T cell responses.[2] T cell responses to E protein epitopes contribute to the overall adaptive immunity against SARS-CoV-2 infection and vaccination, though they are less dominant compared to spike protein epitopes and may exhibit cross-reactivity with other human coronaviruses.[1] This is not a therapeutic target like a receptor or enzyme but rather immunological determinants studied for vaccine design and immune monitoring.[1][2] No drugs directly target these epitopes; research focuses on their role in T cell immunodominance and response kinetics.[1]

Other names

SARS-CoV-2 E protein epitopesenvelope protein-derived T cell epitopes